Assessing MGMT methylation status and its current impact on treatment in glioblastoma.

MGMT promoter methylation status is a strong and independent prognostic factor in patients with newly diagnosed glioblastoma and a clinically relevant predictive marker in the subpopulation of elderly glioblastoma patients. However, there is still lack of consensus on the optimal assay for reliable MGMT promoter methylation testing and a variety of test are being used in different laboratories. Pyrosequencing is the only method for which an adequately high analytical performance (high intra- and interlaboratory repeatability and reproducibility) has been demonstrated in a fully published ring trial. For clinical decision-making MGMT promoter methylation testing should be performed only in experienced laboratories using meticulous validation of assay accuracy. Ideally, such laboratories should undergo regular accreditation through a quality control consortium.

[1]  K. Aldape,et al.  Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[2]  G. Reifenberger,et al.  EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. , 2014, The Lancet. Oncology.

[3]  G. Reifenberger,et al.  MGMT testing—the challenges for biomarker-based glioma treatment , 2014, Nature Reviews Neurology.

[4]  G. Reifenberger,et al.  RESULTS OF THE INTERNATIONAL INTERLABORATORY COMPARISON OF MGMT PROMOTER METHYLATION ANALYSIS INVOLVING TWENTY-THREE ACADEMIC CENTERS IN GERMANY, AUSTRIA AND THE NETHERLANDS , 2014 .

[5]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[6]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[7]  R. Soffietti,et al.  MGMT promoter methylation in plasma of glioma patients receiving temozolomide , 2014, Journal of Neuro-Oncology.

[8]  S. Alibhai,et al.  An update on a systematic review of the use of geriatric assessment for older adults in oncology. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  C. Marosi,et al.  Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma , 2013, Clinical neuropathology.

[10]  Walter J Curran,et al.  Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Reifenberger,et al.  Molecular neuro-oncology in clinical practice: a new horizon. , 2013, The Lancet. Oncology.

[12]  H. Wildiers,et al.  Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  M. Preusser,et al.  Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients – yes, but how? , 2012, Clinical neuropathology.

[14]  G. Reifenberger,et al.  Predictive impact of MGMT promoter methylation in glioblastoma of the elderly , 2012, International journal of cancer.

[15]  Didier Frappaz,et al.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[16]  Michael Weller,et al.  Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. , 2012, Neuro-oncology.

[17]  M. Sanson,et al.  Comparative assessment of 5 methods (methylation‐specific polymerase chain reaction, methylight, pyrosequencing, methylation‐sensitive high‐resolution melting, and immunohistochemistry) to analyze O6‐methylguanine‐DNA‐methyltranferase in a series of 100 glioblastoma patients , 2012, Cancer.

[18]  S. Alibhai,et al.  Use of Geriatric Assessment for Older Adults in the Oncology Setting: A Systematic Review , 2012, Journal of the National Cancer Institute.

[19]  G. Reifenberger,et al.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[20]  G. Lyman,et al.  Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) score , 2012, Cancer.

[21]  R. Lothe,et al.  MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR , 2012, Journal of Translational Medicine.

[22]  M. Weller,et al.  Geriatric neuro-oncology: from mythology to biology. , 2011, Current opinion in neurology.

[23]  R. Stupp,et al.  Current concepts and management of glioblastoma , 2011, Annals of neurology.

[24]  J. Hainfellner,et al.  Fixation of Brain Tumor Biopsy Specimens with RCL2 Results in Well‐Preserved Histomorphology, Immunohistochemistry and Nucleic Acids , 2010, Brain pathology.

[25]  R. Stupp,et al.  Molecular diagnostics of gliomas: the clinical perspective , 2010, Acta Neuropathologica.

[26]  Stephan Saikali,et al.  Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods , 2010, Journal of Neuro-Oncology.

[27]  A. Brunello,et al.  Dose adjustment and supportive care before and during treatment. , 2009, Cancer treatment reviews.

[28]  A. Brodbelt,et al.  Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy , 2009, British Journal of Cancer.

[29]  J. Hainfellner,et al.  Reliability and reproducibility of PCR-based testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens. , 2008, Clinical neuropathology.

[30]  H. Heinzl,et al.  Anti‐O6‐Methylguanine‐Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker * , 2008, Brain pathology.

[31]  J. Pierga,et al.  Does a geriatric oncology consultation modify the cancer treatment plan for elderly patients? , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.

[32]  J. Schramm,et al.  Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. , 2007, The Journal of molecular diagnostics : JMD.

[33]  Lili Liu,et al.  Targeted Modulation of MGMT: Clinical Implications , 2006, Clinical Cancer Research.

[34]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[35]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[36]  K. Bhakat,et al.  Regulation of the HumanO 6-Methylguanine-DNA Methyltransferase Gene by Transcriptional Coactivators cAMP Response Element-binding Protein-binding Protein and p300* , 2000, The Journal of Biological Chemistry.

[37]  J. Costello,et al.  Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene , 1997, Molecular and cellular biology.

[38]  J. Hainfellner,et al.  A simple quantitative diagnostic alternative for MGMT DNA-methylation testing on RCL2 fixed paraffin embedded tumors using restriction coupled qPCR. , 2014, Clinical neuropathology.

[39]  G. Reifenberger,et al.  MGMT promoter methylation in malignant gliomas: ready for personalized medicine? , 2010, Nature Reviews Neurology.

[40]  A. Verma.  MGMT Gene Silencing and Benefit From Temozolomide in GlioblastomaHegi ME, Diserens A-C, Gorlia T, et al (Univ Hosp Lausanne, Switzerland; Univ Hosp Geneva; Swiss Inst for Experimental Cancer Research, Epalinges, Switzerland; et al) N Engl J Med 352:997–1003, 2005§ , 2006 .